Amgen Inc (AMG) Stock Price & News

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia

About Amgen Inc

CEORobert A. Bradway

Employees31.5K

Founded1980

HeadquartersThousand Oaks, California, United States

SectorBiotechnology

Websiteamgen.com

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	9.56B	9.87B	8.62B	10.05B
Cost of goods sold	2.74B	2.68B	2.50B	2.75B
Cost of revenue	2.74B	2.68B	2.50B	2.75B
Research and development expenses	1.90B	2.14B	1.72B	1.87B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.72B	1.95B	1.60B	1.74B
Operating expense	3.55B	4.18B	3.21B	3.73B
Total operating expenses	6.29B	6.85B	5.70B	6.48B
Operating income	3.26B	3.01B	2.91B	3.57B
Other non operating income	181.00M	143.00M	192.00M	145.00M
EBT including unusual items	3.92B	1.51B	2.08B	2.77B
EBT excluding unusual items	2.72B	2.51B	2.37B	3.06B
Income tax expense	705.00M	181.00M	265.00M	393.00M
Effective tax rate	17.98%	11.96%	12.72%	14.20%
Other operating expenses	-71.00M	82.00M	-113.00M	116.00M
Net income	3.22B	1.33B	1.82B	2.38B
Net profit margin	33.65%	13.51%	21.11%	23.62%
Earnings per share	5.64	5.29	5.15	6.29
Interest and investment income	-	408.00M	-	-
Interest expense	-685.00M	-1.06B	-657.00M	-673.00M
Net interest expenses	-685.00M	-653.00M	-657.00M	-673.00M
Depreciation and amortization charges	-	-	-	-
EBITDA	4.57B	4.02B	4.03B	4.69B
Gain or loss from assets sale	-	-	-	-

Ask anything